Research Article

Saireito (114) Increases IC50 and Changes T-Cell Phenotype When Used in Combination with Prednisolone Therapy in Human Peripheral Blood Mononuclear Cells

Figure 6

Concentration of cytokines in the PBMCs after PSL and 114 treatments. ConA, PSL, and 114 were added to PBMCs, and then the solution was incubated for 96 h. For flow cytometry, beads were used to analyze the concentration of TNF, IFN-γ, IL-6, IL-10, IL-17A, and IL-21 in the culture supernatant. Each treatment was compared to its respective blank using Dunnett’s multiple comparisons test (; ). The PSL monotherapy group and the PSL + 114 combination therapy groups were compared using the Tukey–Kramer multiple comparison test (median + SD, n = 6). ConA: concanavalin A, PBMCs: peripheral blood mononuclear cells, PSL: prednisolone, and 114: saireito.
(a)
(b)
(c)
(d)
(e)
(f)